Culture

Phytoplankton -- the discovery of a missing link

Biologists have identified a family of algae as a living missing link in the microscopic domain.

Over the course of evolutionary time, marine microorganisms have undergone an immense range of diversification. This applies in particular to the group known as dinophytes. Also known as dinoflagellates, these unicellular algae can account for a significant fraction of the phytoplankton in the oceans, and their ecological and economic significance is correspondingly high. A team of researchers led by Ludwig-Maximilians-Universitaet (LMU) in Munich biologist Professor Marc Gottschling now reports the identification of a missing link between the two major phylogenetic groups of dinophytes, which sheds new light on the evolution of these organisms.

Many dinophytes are characterized by a bipartite protective structure called a theca, which consists of cellulosic plates synthesized in specialized vesicles that lie immediately below the plasma membrane. The patterning of the plates is often species- and group specific. In the new study, Gottschling and his colleagues focused on a monoclonal dinophyte strain that had been assigned to the Cladopyxidaceae. Using a combination of morphological analysis by electron microscopy and genetic characterization (by ribosomal RNA sequencing), they discovered - much to their surprise - that its phylogenetic position reveals it to be a 'missing link' between the two major groups of thecate dinophytes - the Gonyaulacales and the Peridiniales. In addition, the study showed that this dinophyte represents a new genus and species, which they named Fensomea setacea in honor of the micropaleontologist Robert A. Fensome.

"Missing links have made many important contributions to the understanding of evolution," Gottschling points out. "Among the best known examples among macrofauna are the Urvogel Archaeopteryx and the coelacanth (Latimeria). But the recognition and documentation of a living missing link in the microscopic domain is also highly significant." Up to now, the Cladopyxidaceae have been classified within the Gonyaulacales, while other Dinophyceae with a comparable hyposome were assigned to the Peridiniales." Thanks to the recognition of this missing link, we have now shown that these are misaassignments," says Gottschling. Based on our work the two large groups can now be morphologically defined in a more coherent manner, which clarifies their evolutionary history. The modern Cladopyxidaceae are most probably quite similar to the last common ancestor of all dinophytes, which originated about 200 million years ago. They are the last suvivors of a group that was much more abundant during the times of the dinosaurs."

Credit: 
Ludwig-Maximilians-Universität München

Irritable bowel syndrome endoscopically identifiable from mucosal biofilms

One in six women and one in twelve men in Austria suffers from some form of IBS - therefore around one million people in all. Using currently available techniques, it is only possible to diagnose IBS by a process of elimination. Most people suffering from irritable bowel syndrome only go to their doctor when they have severe symptoms such as constipation, diarrhoea, abdominal pain, or a change in bowel motion. Researchers from the Department of Medicine III of the Medical University of Vienna and the University of Vienna have now shown that, in most cases, IBS is associated with bacterial biofilms in the gut that are visible under endoscopic examination.

"For the first time, we have managed to identify a cause of irritable bowel syndrome and, at the same time, show how this disease can be more accurately diagnosed, classified and assessed," says Christoph Gasche, Head of the Laboratory for Molecular Gastroenterology at Medical University of Vienna and leader of the study funded by the Austrian Science Fund (FWF) and Vienna Science and Technology Fund (WWTF), which has now been published in the leading journal Gastroenterology and came into being in collaboration with MedUni Vienna microbiologist Athanasios Makristathis, David Berry and Markus Muttenthaler (University of Vienna), as well as Timo Rath (Friedrich Alexander University, Erlangen).

According to the study, people who have taken a lot of medication over the course of their lives, so that the balance of their gut flora has been disrupted, are more likely to be affected by bacterial biofilms. Another interesting subgroup is patients who have previously had organ transplants. Gasche explains: "Certain drugs, such as proton pump inhibitors, can upset the balance of the bacterial ecosystem. The bacteria then go into survival mode. To give themselves a better chance of surviving this stress, they band together for safety and form biofilms, a sort of protective space that makes them resistant to antibiotics and other environmental toxins."

In total, more than 1,000 colonoscopies were performed in a multi-centre study, and it was found that two thirds of those who had IBS symptoms also had biofilms in their small or large intestine. However, these mucosal biofilms are also found in one third of patients with ulcerative colitis.

This bacterial matrix, which can be reticular or even planar, adheres like a thin layer on the mucosal lining of the gut - not unlike dental plaque in caries - thereby impairing its functions and, hence, that of the gut. "Up until now, it has always been assumed in investigations that this sticky film is made up of residues of impurities in the gut, which were difficult to eliminate," says Gasche. "However, we have now been able to show that this is where the bacterial matrix adheres." A revolutionary discovery for the lead authors of the study, Maximilian Baumgartner und Michaela Lang, on a par "with the discovery of the rod-shaped bacterium Helicobacter pylori, which permanently changes the gastric environment."

Irrigation might help, biofilms as a new characteristic of IBS

In many cases it is possible to wash away these biofilms in the large intestine using an endoscopic "spray gun". Future studies will show whether this alleviates the IBS symptoms. Also, this technique cannot (as yet) be used to remove biofilms from the small intestine, where they also frequently occur. In a new project funded by Vienna Science and Technology Fund (WWTF), the MedUni Vienna experts are therefore already investigating how the new findings about these biofilms can be used in future to generally remove them or even to prevent them from forming in the first place. But one conclusion can already be drawn from the study results: "Biofilms reflect an imbalance in the gut flora, could well explain the symptoms of IBS patients and, hence, give rise to new therapeutic approaches," say the researchers.

Credit: 
Medical University of Vienna

Baseline medication use is associated with COVID-19 severity in people with rheumatic diseases

Due to sample size limitations, previous studies of DMARD use and COVID-19 outcomes have combined several different rheumatic diseases and medications, and investigated a single outcome- for example, the risk of hospitalization. EULAR has given financial support to a global project collecting information on SARS-CoV-2 infection in people with rheumatic diseases. The COVID-19 Global Rheumatology Alliance physician-reported registry launched in March 2020 to collect data on adults with rheumatic disease and confirmed or presumptive COVID-19.

This analysis from Jeffrey Sparks, Zachary Wallace, and colleagues aimed to investigate the associations between baseline use of biologic or targeted synthetic DMARDs with a range of poor COVID-19 outcomes specifically in people with rheumatoid arthritis (RA). The treatments included were abatacept, rituximab, JAK inhibitors (JAKi), interleukin-6 inhibitors (IL-6i), ortumornecrosis factor inhibitors (TNFi). The outcomes were scored on a scale of one to four for COVID-19 severity: 1) no hospitalization, 2) hospitalization without oxygen need, 3) hospitalization with any oxygen need or ventilation, or 4) death. The authors used an analysis to compare each drug class toTNFi.

Of 1,673 people with RA taking b/tsDMARDs when they developed COVID-19, 498 (34.3%) were hospitalized and 112 (6.7%) died. Rituximab users were more likely than TNFi users to have interstitial lung disease(ILD;11.6% versus1.7%) and history of cancer (7.1%versus2.0%); JAKi users were more likely than TNFi users to be obese (17.3%versus9.0%). After propensity score matching, the authors found that rituximab was strongly associated with greater odds of having a worseCOVID-19outcome compared to TNFi. Among rituximab users, 42 (18.8%) died compared to 27 (3.3%) of TNFi users. JAKi use was also associated with greater odds of having a worse COVID-19 severity. People taking abatacept orIL-6ididnot have worseCOVID-19 severity compared to TNFi. Overall, the results were similar in the sensitivity analysis and after excluding cancer or ILD.

Since the abstract was submitted, Sparks adds that the database was refreshed so the numbers have all changed and the sample size is bigger. The main findings are consistent with the initial submission.

Similar results regarding rituximab have been found in the French RMD cohort. Avouac and colleagues reported findings on behalf of a consortium of contributors, includingFAI2R,SFR,SNFMI,SOFREMIP,CRI, and IMIDIATE. Of 1,090peopleincludedwith rheumatic diseases - mainly RA -137 developed severeCOVID-19disease (12.6%). After adjusting for potential confounding factors, severe disease was confirmed to be more frequent in patients receiving rituximab. People who developed severeCOVID-19hadreceived rituximab infusion more recently compared to people with mild or moderate infection.

In this cohort, 89 people cohort died-an overall death rate of 8.2%. Death rate was numerically higher in people receiving rituximab(20.6%) compared to those not(7.4%),and the subgroup of untreated patients with diseases eligible for rituximab therapy (9.9%).However, after adjusting for confounding factors, the risk of death was not significantly increased in people treated with rituximab, although the length of hospital stay was markedly longer in people treated with rituximab compared to both untreated groups.

Results so far from these registriesof people with RA and COVID-19show that baseline use of rituximab or JAKiis associated with worse severity of COVID-19 compared to TNFi use. The elevated odds for poor COVID-19 outcomes in people taking rituximab highlights the urgent need for strategies to limit their risk, such as optimal vaccination timing. The global alliance finding that JAKi are associated with poor COVID-19 outcomes is novel, and needs to be reproduced in other studies.

Credit: 
European Alliance of Associations for Rheumatology (EULAR)

Climate warming can influence fungal communities on oak leaves across the growing season

image: View inside one of the three heated cages in the experiment.

Image: 
Maria Faticov

Climate warming plays a larger role than plant genes in influencing the number and identity of fungal species on oak leaves, especially in autumn. Recently published in the journal New Phytologist, this research by ecologists sheds light on how warming and tree genes affect the dynamics of fungal communities across the season.

"One of our major findings was that elevated temperature decreased the number of fungal species and changed their community composition, especially in the late season" says Maria Faticov, a researcher at the Department of Ecology, Environment and Plant Sciences (DEEP) at Stockholm University.

Plants host thousands of microscopic organisms and leaves are no exception. Leaves harbour a large diversity of microorganisms including fungi, bacteria and, less frequently, archaea. Fungi are among the most diverse groups of microorganisms living on leaves. Some of these microscopic fungi cause disease, others can promote plant growth and defend leaves against biotic and abiotic stresses, and still others play an important role in leaf senescence and decomposition.

Climate is one of the main factors influencing fungal development, either directly or indirectly, by triggering plant defences.

"From earlier studies, we know that the number of fungal species and their abundance change as leaves age and the season progresses from spring to autumn. What we do not know is what role climate warming and plant genetic variation play in shaping fungal communities across the growing season" says Ayco Tack, associate professor at the Department of Ecology, Environment and Plant Sciences, Stockholm University.

To answer this question, researchers took on a challenging project - they built 6 identical cages in a field to the north of Stockholm, each cage the size of a small living room. Scientists put 132 young oak trees into the cages that represented 5 different genotypes. Half of the cages were heated from May to October using ceramic heaters. The remaining ones were left as control and did not have heaters in them. The temperature in the heated cages was increased by ca 2°C to mimic the global temperature increase predicted by scientists to occur by the end of the century. Researchers collected leaves in the early, middle and late growing season and used DNA sequencing to find out which fungi had colonised the leaves. This way they could compare the changes in fungal community structure between the control and warming treatment and also among oak genotypes.

"We observed that fungal community composition drastically changed from spring to autumn, with yeasts increasing in relative abundance and fungal pathogens decreasing. Interestingly, while experimental warming had a major impact on the fungal community, oak genotype explained only a minor part of the variation in the number of fungal species and their composition" says Maria Faticov.

These findings suggest that warming is one of the most important environmental factors shaping fungal community development during the growing season and emphasizes how profound the effects of ongoing climate change may be to plant health and ecosystem functioning.

Researchers did not link the observed change in fungal community structure under warming with plant health and ecosystem functioning. More detailed long-term experiments are needed to predict how changes in the fungal community under climate warming will influence the plants they live on and their surrounding environment.

"In future studies, it will be interesting to investigate how these changes in the number of fungal species and their abundances under warmer climate impact such important processes as plant health, leaf senescence and litter decomposition" says Maria Faticov.

Credit: 
Stockholm University

Imaging at the tip of a needle

image: Once the key to unscrambling the images has been measured, it is possible to image through the optical fiber -- turning it into an ultra-thin endoscope. Shown are some experimentally measured images of a resolution target. Each image is one twentieth of a millimeter wide (about the same width as a strand of hair).

Image: 
University of Exeter

Scientists have developed a new technique that could revolutionise medical imaging procedures using light.

A team of physicists, led by Dr David Phillips from the University of Exeter, have pioneered a new way in which to control light that has been scrambled by passage through a single hair-thin strand of optical fibre. These ultra-thin fibres hold much promise for the next generation of medical endoscopes - enabling high-resolution imaging deep inside the body at the tip of a needle.

Conventional endoscopes are millimetres wide and have limited resolution - so cannot be used to inspect individual cells. Single optical fibres are approximately 10x narrower and can enable much higher-resolution imaging - enough to examine the features of individual cells directly inside living tissue. It is normally only possible to view cells once they have been taken outside the body and placed in a microscope.

The catch is that we can't directly look through optical fibres, as they scramble the light sent through them. This problem can be solved by first calibrating an optical fibre to understand how it blurs images, and then using this calibration information as a key to decipher images from the scrambled light. Earlier this year, Dr Phillips' group developed a way to measure this key extremely rapidly, in collaboration with researchers from Boston University in the USA, and the Liebniz Institute of Photonic Technologies in Germany [paper: Compressively sampling the optical transmission matrix of a multimode fibre, published in Light: Science and Applications, April 21st 2021].

However, the measured key is very fragile, and easily changes if the fibre bends or twists, rendering deployment of this technology in real clinical settings currently very challenging. To overcome this problem, the Exeter based team have now developed a new way to keep track of how the image unscrambling key changes while the fibre is in use. This provides a way to maintain high resolution imaging even as a single fibre based micro-endoscope flexes. The researchers achieved this by borrowing a concept used in astronomy to see through atmospheric turbulence and applying it to look through optical fibres. The method relies on a 'guide-star' - which in their case is a small brightly fluorescing particle on the end of the fibre. Light from the guide-star encodes how the key changes when the fibre bends, thus ensuring imaging is not disrupted.

This is a key advance for the development of flexible ultra-thin endoscopes. Such imaging devices could be used to guide biopsy needles to the right place, and help identify diseased cells within the body.

Dr Phillips, an Associate Professor in the Physics and Astronomy department at the University of Exeter, said: "We hope that our work brings the visualisation of sub-cellular processes deep inside the body a step closer to reality - and helps to translate this technology from the lab to the clinic."

The latest work is in collaboration with researchers at the Liebniz Institute of Photonic Technologies in Germany, and the Brno Insititute of Scientific Instruments in the Czech Republic. The project was made possible with funding from the Royal Academy of Engineering and the Royal Society in the UK, the European Research Council, and the Chinese Scholarship Council.

Memory effect assisted imaging through multimode optical fibres is published in Nature Communications on Friday, June 18th 2021

Credit: 
University of Exeter

Decline in excess risk of dementia and heart failure in patients with rheumatoid arthritis

RA is an inflammatory autoimmune disease that causes pain, swelling and stiffness in the joints. It can also cause fatigue, and the underlying inflammation may affect other body systems. Dementia is a symptom of damage to the brain, which can be caused by a number of different diseases - for example, Alzeimer's. Symptoms include memory loss, difficulty concentrating, confusion, and mood changes. It is not known what causes all types of dementia, but it is it thought that some of the damage could be caused by other underlying diseases. Heart failure happens when the heart becomes weak or stiff, and is not able to pump blood around the body properly. People with heart failure may be breathless even when at rest, feel very tired, and have swollen ankles or legs.

Heart failure is one of the most common cardiovascular conditions in people with RA, and previous studies have suggested that people with RA are twice as likely to develop heart failure as people in the general population without RA. For dementia, previous studies have delivered mixed results about the pattern of cognitive impairment and dementia in people with RA compared to the general population- with some showing increased odds, while others show the reverse. Furthermore, existing studies have not evaluated trends in incidence of dementia or heart failure to see if the risks have changed over time.

Two groups at the Mayo Clinic, USA have run population-based studies in Minnesota to assess the incidence of dementia or heart failure over time in people with RA, and compared to the general population.

Vanessa Kronzer and colleagues assessed the incidence of dementia over time in people with RA and compared it to that seen in the general population. Medical record data were collected for 895 people diagnosed with RA between 1980 and 2009. All individuals were followed until death, migration, or31st December2019to see if they went on to develop dementia. The 10-year cumulative incidence of dementia in people diagnosed during the1980s, 1990s, and 2000s was 12.7%, 7.2%, and 6.2%, respectively - showing a clear decline and markedly lower cumulative incidence of dementia for people diagnosed with RA in the2000s compared with the1980s. For 880 people in the general population without RA, the10-year cumulative incidence of dementia in the 1980s, 1990s, and 2000swas 9.3%,5.0%, and7.1%, respectively. Overall, the risk of dementia in RA patients was significantly higher than in people without RA. When subdivided by decade, the risk of dementia in people diagnosed with RA was higher than non-RA comparators in the 1980s and 1990s-but notthe2000s.

Elena Myasoedova and colleagues used the same methods to look at the trends of heart failure in 905 people diagnosed with RA between 1980 and 2009, and followed until death, migration, or31stDecember2019.The 10-year cumulative incidence of heart failure in people diagnosed with RA in the1980s, 1990s, and 2000s was 8.5%,10.8%, and7.1%, respectively. These results show there was no difference in incidence of heart failureinthe1990s and 2000s compared tothe1980s.For903 people in the general population without RA over the same time period the incidence of heart failure was 7.4%,7.5%,and 7.3%.When comparing the risk of heart failure in people with and without RA, those diagnosed with RA in the 2000s had no excess risk of heart failure compared to the general population. This finding is in contrast to the 2-fold excess risk seen in people diagnosed with RA in the1980s, and around1.5-fold increased risk in 1990s.

Further studies should investigate these association, and look at the role of inflammation, autoimmunity, and anti-rheumatic treatments in the risk of dementia and heart failure.

Credit: 
European Alliance of Associations for Rheumatology (EULAR)

Inflammation of the eye after drug withdrawal in children with arthritis

Uveitis occurs in up to 20% of children with JIA, although this varies depending on the specific type of JIA that each child has. Jens Klotsche and colleagues shared new data at the 2021 EULAR congress analysing the risk of uveitis events after discontinuing disease-modifying antirheumatic drugs (DMARD) in children with one of two JIA categories: extended oligoarthritis and rheumatoid factor (RF)-negative polyarthritis.

The data for the analysis came from two ongoing biologic registers: the German Biologics in Pediatric Rheumatology (BiKeR) registry, and the Juvenile arthritis Methotrexate/Biologics long-term Observation (JuMBO) study. Adverse events and reports about uveitis events during treatment and after discontinuation of DMARDs were collected. A total of 2,041children with RF-negative polyarthritis or extended oligoarthritis were included. About half of the patients were enrolled in BiKeR when they started taking etanercept (n=1,137;55.7%), followed by 635 (31.1%) patients starting methotrexate monotherapy, or adalimumab (n=198, 9.7%). A history of uveitis was reported for 11.7%of children at enrolment in BiKeR.

Children with uveitis had a lower age at JIA onset in comparison to patients without uveitis. A total of 142 recurrent uveitis events were reported in 93 children, and for 27 children this was an incident uveitis reported during follow-up, with 19 uveitis flares reported for patients after the age of 18.

Uveitis events were reported significantly more often in the first 24 months after methotrexate discontinuation, and in the first 3 months after biological DMARD discontinuation (adalimumab and etanercept). Children with amethotrexate dose of 10 mg/m²or less at last intake had a higher likelihood for uveitis events. Overall, the longer the time since DMARD discontinuation the fewer uveitis events occurred.

This is the first prospective study to look at the risk of uveitis after DMARD withdrawal. The findings show uveitis relapses are common. Patients who stop DMARD therapy are at high risk for uveitis within the first 3-24 months after discontinuation. Rheumatologists and ophthalmologists should be aware about this risk, which should lead to regular uveitis screening after DMARD withdrawal.

Credit: 
European Alliance of Associations for Rheumatology (EULAR)

Evolution -- two routes to the same destination

Fruit flies have found at least two solutions to the problem of sorting their sex chromosomes: a matter of life and death.

Sex determination in animals often depends on the unequal segregation of specific chromosomes. Female cells generally possess two X chromosomes, while male cells contain one X and one Y chromosome. The latter, which is inherited from the male parent, has far fewer genes than the X. In the fruit fly Drosophila, male cells make up for the fact that they have only one X chromosome by boosting the level of expression of all of its genes by a factor of 2. This phenomenon, which is known as dosage compensation, requires that the X chromosome in males be regulated differently from all the others. A team of molecular biologists at Ludwig-Maximilians-Universitaet (LMU) in Munichs Biomedical Center led by Professor Peter Becker has now shown that, over the course of 40 million years, members of the genus Drosophila have discovered at least two different ways of making this vital distinction.

"In light of the significance of dosage compensation, one might expect that the principles behind the specific recognition of the X chromosome in males would be highly conserved," says Becker. "In other words, the process should work in essentially the same way in all Drosophila species. However, when we compared the two species Drosophila melanogaster and Drosophila virilis, we discovered, to our surprise, that they use distinct mechanisms for this purpose." Significantly, the primary components involved in dosage compensation - the proteins MSL2 and CLAMP, together with the non-coding RNA roX - are found in both species. So their last common ancestor presumably possessed the genes that code for these products.

The two species diverged about 40 million years ago, and since then they have evolved in parallel. The new study shows that, during this period, the mediators of dosage compensation and their binding sites on the X chromosome have evolved in different ways. As a result, the relative influence of, and the interactions between, the components have changed. Among other things, in D. melanogaster the copy numbers of certain DNA sequences on the X chromosome have increased. In parallel, the DNA-binding domain of the MSL2 protein has acquired the ability to recognize these sequences, and they now play a critical role in the recognition of the X chromosome in this species.

In D. virilis, on the other hand, these sequences have not been amplified. Their recognition by MSL2 therefore depends on its interaction with the CLAMP protein to a much greater extent than in the case of D. melanogaster - even though the CLAMP protein can also bind to many sequences on the other chromosomes. "We assume that the non-coding roX RNA inhibits the binding of MSL2 at these sites", says Becker. The study has therefore uncovered a new role for this RNA. Up until now, researchers had assumed that roX comes into play not at the level of sequence recognition, but at a later stage in the dosage compensation process.

These findings have interesting evolutionary implications. "As the sex chromosomes continue to diversify, the emergence of alternative but equally effective solutions to the problem of balancing the activity of the genome demonstrates that evolution is not a deterministic process," Becker points out.

Credit: 
Ludwig-Maximilians-Universität München

VIMS study uncovers new cause for intensification of oyster disease

image: Panel A shows the original form of the Dermo parasite Perkinsus marinus, with black arrows indicating typical Dermo cells and the white arrow a dividing form, all infecting connective tissues deep inside an oyster. Panel B shows the new form of the parasite, much smaller, with the arrow indicating a mass of dozens of Dermo cells inside a single oyster blood cell, and primarily infecting the lining of the stomach and gut.

Image: 
© R. Carnegie/VIMS.

A new paper in Scientific Reports led by researchers at William & Mary's Virginia Institute of Marine Science challenges increased salinity and seawater temperatures as the established explanation for a decades-long increase in the prevalence and deadliness of a major oyster disease in the coastal waters of the mid-Atlantic.

Dr. Ryan Carnegie, the paper's lead author, says "We present an entirely new lens through which we can view our last 35 years of oyster history in the Chesapeake Bay region. We now know the great intensification of Dermo disease in the 1980s wasn't simply due to drought. It was more fundamentally due to the emergence of a new and highly virulent form of Perkinsus marinus, the parasite that causes Dermo."

In an unusual twist, the team's evidence suggests that transformation of this native parasite was in response to evolutionary pressures brought by the impacts of another, non-native oyster parasite known as MSX, first seen in Bay waters in 1959. Dermo's mid-80s rise in virulence, along with decades of overharvesting, habitat destruction, and the earlier devastation of MSX, brought the Bay's traditional oyster fishery to a historic low.

Carnegie says his team's findings can help better manage the Bay's modern oyster industry, which is now on the upswing due to disease-resistant aquaculture strains, reef restoration, and limits on the wild harvest. "The lesson," he says, "is that pathogens like P. marinus are highly dynamic, and our disease surveillance must be attentive to any changes that may occur. This includes the emergence of more virulent strains, or variants that may have different forms or life histories than we expect. Management should be continually tuned to any changes in disease dynamics."

The team's findings also give scientists and fishery managers a better understanding of the "rock-bottom" era for Bay oysters between the late 1980s and early 2000s. "The oysters reached this level of devastation not because they were unable to deal with Dermo after decades, if not centuries or millennia, of exposure," says Carnegie. "They hit rock bottom because they were challenged with a brand-new form of the parasite, and needed time to adapt. And now they are adapting, which is key to the oyster's recent recovery in the region."

Along with Carnegie, the paper's other authors are the late Susan Ford of Haskin Shellfish Research Laboratory at Rutgers University; Peter Kingsley-Smith of the South Carolina Department of Natural Resources; and Rita Crockett, Lydia Bienlien, Lúcia Safi, Laura Whitefleet-Smith, and Eugene Burreson of VIMS. Funding for the study comes from the VIMS Foundation A. Marshall Acuff, Sr., Memorial Endowment for Oyster Disease Research.

Evidence for a more virulent Dermo parasite

Dermo disease results when the eastern oyster Crassostrea virginica is infected by the protozoan parasite Perkinsus marinus. Infected oysters grow more slowly, exhibit poorer body condition, and reproduce less successfully than their healthy counterparts. Severe infections lead to oyster death and release of parasites into the surrounding water, potentially infecting other nearby oysters as they filter water for food. The disease does not affect people who eat the shellfish.

Native to the Gulf Coast, Dermo was first recorded in the Chesapeake Bay in 1949, though it had likely been there far longer. Prior to the 1980s, it typically occurred as a chronic disease that killed about 30% of oysters annually, mostly older animals that had been exposed to the parasite for several years. But, says Carnegie, "Around 1986, Dermo suddenly became an acute and profoundly destructive disease capable of killing more than 70% of host oysters within months of infection." The increased virulence of the Perkinsus parasite persists today.

Because the parasite's infectiousness is known to increase with higher salinity, scientists initially attributed the mid-1980s spike in Dermo's virulence to a multi-year drought that had struck the mid-Atlantic around that time, raising coastal salinities as freshwater input from rivers decreased. Increasing seawater temperatures also promote increased Dermo disease, and ocean warming has been blamed for the northward increase in Dermo's range since the 1980s. As time passed, however, Carnegie and other researchers began to realize that salinity and temperature alone did not fully explain the lasting increase in Dermo infections and associated oyster mortality along the East Coast.

"We began to ask why more protracted and intense droughts in earlier years, before the 1980s, hadn't produced a similar intensification of disease," says Carnegie, "and why subsequent wet periods didn't return the parasite to the low levels of infection characteristic of earlier years."

Motivated by these questions, Carnegie and colleagues compared samples from modern Bay oysters with samples taken in 1960 and stored at VIMS, using paper-thin tissue slices glued onto slides for viewing under a microscope. Finding striking and unexpected differences, they then took a comprehensive look at more than 8,000 tissue samples collected from oysters in Chesapeake Bay, South Carolina, and New Jersey between 1960 and 2018.

"Our analysis," says Carnegie, "clearly showed that a new parasite variant emerged between 1983 and 1990, concurrent with the historical mid-80s outbreaks of Dermo." Changes included a shift in the infection site--from deeper connective tissues to the lining of the digestive tract--changes in reproductive strategy, and a sharp decrease in cell size. In Chesapeake Bay, they found the most pronounced change between oysters sampled in 1985 and 1986, when the modern variant increased in frequency from 22% to 99% of observations.

"The picture that emerges," says Carnegie, "is the rise of a virulent new form of the Dermo parasite Perkinsus along the mid-Atlantic coast in the mid-80s, which dispersed from there and supplanted a form that previously had been widely distributed in Atlantic estuaries. While changes in pathogen virulence have been documented in other systems, the scope of changes we've seen, and their rapid spread across a wide area, is unusual."

"Our work underscores the importance of long-term environmental monitoring," he adds. "Without that, and the maintenance of associated natural history collections, this new perspective wouldn't have been possible."

Evolutionary pressures

The type of changes observed in the Dermo parasite suggest they represent a novel but predictable response to the devastating impacts of MSX, the disease caused by the non-native parasite Haplosporidium nelsoni, which was first reported in Bay waters in 1959. MSX killed more than 90% of Virginia's farmed oysters by 1961, and slashed the harvest of planted oysters from 3,347,170 bushels in 1959 to 361,792 bushels by 1983, an estimated loss of 1.8 billion animals. This decrease was likely compounded by simultaneous losses from wild populations.

A parasite that quickly kills its host effectively destroys its own home. Over evolutionary time scales, natural selection thus often leads to an equilibrium between a native parasite and its host, marked by the type of minor, long-term Perkinsus infections and low rates of Dermo mortality historically observed in Chesapeake Bay oysters.

But when a new parasite arrives on the scene, that evolutionary balance may shift. Carnegie and his team speculate that the devastating arrival of the non-native, MSX parasite in Bay waters drastically disrupted the long-established equilibrium between Dermo and Crassostrea, directly leading to the new, more virulent form of the disease.

"A huge reduction in oyster abundance--like that caused by the arrival of MSX--would severely impact a parasite such as P. marinus that depends entirely on a single host," says Carnegie. As evidence, he notes that Perkinsus declined sharply in abundance beginning in 1959; recent theoretical modeling underscores the possibility that an increase in parasite virulence could be a consequence of such reduction in host resources.

"The changes we saw in the Dermo parasite are likely adaptive with regard to the reduced oyster abundance and longevity it faced after rapid establishment of Haplosporidium nelsoni and MSX in 1959," says Carnegie. "Our findings, we hypothesize, illustrate a novel ecosystem response to a marine parasite invasion: an increase in virulence in a native parasite." An intriguing possibility is that the changes the researchers observed may represent a shortening of the Perkinsus life cycle, as it adapted to oysters with shorter life spans due to mortality from MSX.

Credit: 
Virginia Institute of Marine Science

An increase in giant cell arteritis cases associated with peaks in COVID-19 prevalence

Ben Mulhearn and colleagues estimated the incidence of GCA seen during the COVID-19 pandemic and compared it to data from 2019, before the pandemic hit. The two distinct peaks of COVID-19 reflected by UK hospital admissions of COVID-19-positive patients allowed the authors to investigate the relationship in time between COVID-19 and GCA incidence.

At the Royal National Hospital for Rheumatic Diseases in Bath, UK, there were 61 probable or definite GCA diagnoses made in 2020 compared to 28 in 2019- representing an excess of 33 cases in 2020, or an increase of 118%.Taking into account the fact that41% of the hospital's catchment population is over the age of 50, this equates to an annual incidence rate of 13.7 per 100,000 in 2019 and 29.8 per 100,000 in 2020. The previously estimated regional incidence rate for South West of the UK was 21.6 per 100,000.

The significantly increased incidence of GCA may be the result of widespread infection in the local population,withSARS-CoV-2 as a driving factor. Possible mechanisms include, but are not limited to, endothelial disruption by the virus, immune system priming towards T helper cell type 1 cellular immunity, and activation of the monocyte-macrophage system. More work is underway to assess the causal relationship between the two diseases, and it may be important to monitor the number of referrals for GCA as the pandemic continues.

Credit: 
European Alliance of Associations for Rheumatology (EULAR)

Two U of M Medical School studies provide new evidence to battle drug price increases

MINNEAPOLIS/ST. PAUL (06/18/2021) -- Two recent studies led by researchers from the University of Minnesota Medical School add new evidence to the impact of how drug price increases affect U.S. patients and the overall cost of health care.

The first study, published today in the JAMA Network Open, provides new data on how dramatic increases in anti-infective drug prices altered the overall cost of outpatient health care and decreased patient access to appropriate drug treatment. The study protocol was reviewed by the U.S. Centers for Disease Control and Prevention and scanned more than 100 million de-identified patient records to find roughly 89,000 cases of interest between 2010 and 2018. The results showed that:

A standard-of-care (SOC) drug to treat hookworm increased from $32.77 to $1,660, which correlated with a decrease in patients receiving an appropriate drug from 43 percent to 28 percent.

A SOC drug to treat pinworm increased from $14.81 to $130, which correlated with a decrease in patients receiving an appropriate drug from 81 percent to 28 percent.

A SOC drug to treat Clostridioides difficile (a control with little price change) remained mostly stable, increasing from $53 to $68, which correlated with an increase in patients receiving an appropriate drug from 69 percent to 77 percent.

"Our study shows that dramatic drug price increases lead to much higher outpatient costs and decrease appropriate drug treatment due to access issues and health care professionals switching to a substandard drug," said co-first author of the study, William Stauffer, MD, MSPH, FASTMH, who is a professor of medicine at the U of M Medical School. "More studies need to be done to confirm these findings, but this should increase policymakers attention as they consider solutions to extreme drug pricing."

The second study looked at state legislative action on the issue so far. Published in the Journal of General Internal Medicine, the research team reviewed all U.S. state laws enacted since 2015 to address drug price increases, as well as state bills being considered in 2020, and found several shortcomings. The study has two recommendations:

Transparency laws were the most common type of legislative action, however, many of the transparency bills considered in 2020 don't require transparency until after the price increases occur -- some up to one year after. The study recommends requiring transparency before price increases occur, so that vulnerable patients have time to seek alternative treatment options.

Of those states that created affordability review bills, only 22 percent specify OPOE (off-patent, off-exclusivity) brand-name drugs, which are cheaper than patent-protected, brand-name drugs and more prone to price hikes -- as demonstrated by this team's 2020 study. The study recommends creating separate review thresholds for OPOE drugs to ensure they are not misclassified as brand-name drugs, which are allowed higher price increase thresholds.

"Prescription drug price increases inflate national health spending and are disproportionately felt by patients who are uninsured or have high deductibles," said Arman Shahriar, a U of M Medical School student and first author of the study. "Despite prescription drug price increases being a known problem for years, little has been done at the federal level, and states have not been unified in their approach. We want to make state lawmakers aware of the current landscape and future directions of this legislation."

Credit: 
University of Minnesota Medical School

Use rewards effectively to boost creativity

HOUSTON - (June 18, 2021) - To boost employees' creativity, managers should consider offering a set of rewards for them to choose from, according to a new study by management experts at Rice University, Tulane University, the University of North Carolina at Greensboro and National Taiwan Normal University.

The study, co-authored by Jing Zhou, the Mary Gibbs Jones Professor of Management and Psychology at Rice's Jones Graduate School of Business, is the first to systematically examine the effects of reward choice in a field experiment, which was conducted in the context of an organizationwide suggestion program. An advance copy of the paper is published online in the Journal of Applied Psychology.

"Organizations spend a lot of resources and exert a great deal of effort in designing incentive schemes that reward the employees who exhibit creativity at work," Zhou said. "Our results showed that the effort may be a bit misplaced. Instead of discovering one reward type that is particularly effective at promoting creativity, what is more effective is to provide the employees with the opportunity to choose from several reward types, if they submit one or more ideas that are among the top 20% most creative ones."

Workers in the study were given a range of options: a financial reward for the individual employee or their team, a self-discretionary reward such as getting priority to select days off, or a donation the company made to a charity selected by the employee. Those choices had positive, significant effects on the number of creative ideas employees generated and the creativity level of those ideas, Zhou and her co-authors found.

The researchers arrived at their findings by conducting a quasi-experiment at a company in Taiwan over the course of several months. Then they conducted a second experimental study that included employees from 12 organizations in Taiwan to replicate the first study's results and compared the results with a control group.

The studies also found that rewards aimed at helping others, such as making a donation to a charity, might be especially powerful. But for less-creative employees, alternative rewards that benefit those in need might actually lower creativity and should be avoided, the authors said.

The researchers also found that the choice of rewards fostered creativity by raising the employees' belief in their ability to be creative. Alternative rewards also had a powerful impact on boosting the creativity of employees who earlier had scored high on an assessment of creative personality characteristics.

Credit: 
Rice University

Researchers find losartan is not effective in reducing hospitalization from mild COVID-19

MINNEAPOLIS/ST. PAUL (06/18/2021) -- University of Minnesota Medical School researchers determined that the common blood pressure medication, losartan, is not effective in reducing hospitalization for mildly-ill COVID-19 outpatients.

In the multicenter, randomized, double-blinded clinical trial, non-hospitalized patients recently diagnosed with COVID-19 were given either losartan or a placebo and monitored for 15 days. The study's results, which were published in EClinicalMedicine, showed that although losartan does not reduce the likelihood of hospitalization, the medication does not appear to worsen symptoms of COVID-19 or have any significant or harmful side effects on patients with mild COVID-19.

"Based on our results, there is no benefit to starting losartan for newly diagnosed outpatients with COVID-19, but those who are already taking the medication for pre-existing health conditions should feel safe continuing it," said Michael Puskarich, MD, an associate professor in the Department of Emergency Medicine at the U of M Medical School and co-principal investigator of this study. He is also an emergency physician at Hennepin Healthcare.

Conflicting hypotheses since the start of the pandemic led this research team to investigate losartan as a potential treatment option. While some experts believed drugs like losartan may reduce inflammation and help those infected recover, others worried that the drug could worsen COVID-19 symptoms.

"Given SARS-CoV-2 binding with ACE2 there has been significant research interest into the utility of ACE and AT1R blocking agents to combat COVID-19. This study provides insight that for patients with mild COVID-19, who do not require hospital admission, that there is no benefit or harm from such agents," said co-principal investigator Christopher Tignanelli, MD, MS, an assistant professor in the Department of Surgery at the U of M Medical School and critical care surgeon with M Health Fairview.

The same team has been working on another trial for inpatients to evaluate if losartan prevents lung injury in hospitalized patients with COVID-19 pneumonia. They have completed enrollment and are currently analyzing the data.

Credit: 
University of Minnesota Medical School

Scientists detect signatures of life remotely

image: The FlyPol instrument, which was used to measure biosignatures from the air, aboard the helicopter.

Image: 
Courtesy of Lucas Patty

Left hands and right hands are almost perfect mirror images of each other. But whatever way they are twisted and turned, they cannot be superimposed onto each other. This is why the left glove simply won't fit the right hand as well as it fits the left. In science, this property is referred to as chirality.

Just like hands are chiral, molecules can be chiral, too. In fact, most molecules in the cells of living organisms, such as DNA, are chiral. Unlike hands, however, that usually come in pairs of left and right, the molecules of life almost exclusively occur in either their "left-handed" or their "right-handed" version. They are homochiral, as researchers say. Why that is, is still not clear. But this molecular homochirality is a characteristic property of life, a so-called biosignature.

As part of the MERMOZ project (see info box), an international team led by the University of Bern and the National Centre of Competence in Research NCCR PlanetS, has now succeeded in detecting this signature from a distance of 2 kilometers and at a velocity of 70 kph. Jonas Kühn, MERMOZ project manager of the University of Bern and co-author of the study that has just been published in the journal Astronomy and Astrophysics, says: "The significant advance is that these measurements have been performed in a platform that was moving, vibrating and that we still detected these biosignatures in a matter of seconds."

An instrument that recognizes living matter

"When light is reflected by biological matter, a part of the light's electromagnetic waves will travel in either clockwise or counterclockwise spirals. This phenomenon is called circular polarization and is caused by the biological matter's homochirality. Similar spirals of light are not produced by abiotic non-living nature", says the first author of the study Lucas Patty, who is a MERMOZ postdoctoral researcher at the University of Bern and member of the NCCR PlanetS,

Measuring this circular polarization, however, is challenging. The signal is quite faint and typically makes up less than one percent of the light that is reflected. To measure it, the team developed a dedicated device called a spectropolarimeter. It consists of a camera equipped with special lenses and receivers capable of separating the circular polarization from the rest of the light.

Yet even with this elaborate device, the new results would have been impossible until recently. "Just 4 years ago, we could detect the signal only from a very close distance, around 20 cm, and needed to
observe the same spot for several minutes to do so", as Lucas Patty recalls. But the upgrades to the instrument he and his colleagues made, allow a much faster and stable detection, and the strength of the signature in circular polarisation persists even with distance. This rendered the instrument fit for the first ever aerial circular polarization measurements.

Useful measurements on earth and in space

Using this upgraded instrument, dubbed FlyPol, they demonstrated that within mere seconds of measurements they could differentiate between grass fields, forests and urban areas from a fast moving helicopter. The measurements readily show living matter exhibiting the characteristic polarization signals, while roads, for example, do not show any significant circular polarization signals. With the current setup, they are even capable of detecting signals coming from algae in lakes.

After their successful tests, the scientists now look to go even further. "The next step we hope to take, is to perform similar detections from the International Space Station (ISS), looking down at the Earth. That will allow us to assess the detectability of planetary-scale biosignatures. This step will be decisive to enable the search for life in and beyond our Solar System using polarization", says MERMOZ principal investigator and co-author Brice-Olivier Demory, professor of astrophysics at the University of Bern and member of the NCCR PlanetS says.

The sensitive observation of these circular polarization signals is not only important for future life detection missions. Lucas Patty explains: "Because the signal directly relates to the molecular composition of life and thus its functioning, it can also offer valuable complementary information in Earth remote sensing." It can for instance provide information about deforestation or plant disease. It might even be possible to implement circular polarization in the monitoring of toxic algal blooms, of coral reefs and the effects of acidification thereon.

Credit: 
University of Bern

Team describes science-based hiccups intervention

image: The Forced Inspiratory Suction and Swallow Tool, shown here, is designed to stop hiccups on one or two attempts. It was developed at The University of Texas Health Science Center at San Antonio.

Image: 
Figure courtesy of JAMA Network Open

SAN ANTONIO (June 18, 2021) -- Researchers from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) and colleagues worldwide describe a new science-based intervention for hiccups in a research letter published June 18 in the journal JAMA Network Open.

In the publication, the scientists coined a new term for the intervention: the "forced inspiratory suction and swallow tool," or FISST. The team also reported the results of a survey of 249 users who were asked whether it is superior to hiccup home remedies such as breathing into a paper bag.

The need

"Hiccups are occasionally annoying for some people, but for others they significantly impact quality of life," said Ali Seifi, MD, associate professor of neurosurgery in UT Health San Antonio's Joe R. and Teresa Lozano Long School of Medicine. "This includes many patients with brain and stroke injury, and cancer patients. We had a couple of cancer patients in this study. Some chemotherapies cause hiccups."

Simple tool

FISST is a rigid drinking tube with an inlet valve that requires forceful suction to draw water from a cup into the mouth. The suction and swallow simultaneously stimulate two nerves, the phrenic and vagus nerves, to relieve hiccups.

Forceful suction induces the diaphragm, a sheaf of muscle that inflates the lungs during breathing, to contract. The suction and swallow also prompt the epiglottis, a flap that covers the windpipe during swallowing, to close. This ends the hiccup spasms.

User feedback

FISST stopped hiccups in nearly 92% of cases, users self-reported. In terms of satisfaction, 226 of 249 participants (90.8%) affirmatively answered questions about whether they found the tool easy to use.

On a different measure, subjective effectiveness, 183 of 203 participants (90.1%) indicated that FISST was effective when they used it. Fewer participants answered this question, possibly because it was last in the survey, Dr. Seifi said.

The tool, developed at UT Health San Antonio by Dr. Seifi with input from medical students, is being marketed by a Colorado company under a license agreement with the university and has been accepted by a major supermarket chain to be placed on shelves, Dr. Seifi said.

About the study

The research project began with 600 individuals who, because they stated they had hiccups, received FISST. Of this population, 290 persons responded to a survey about their experience with using the device, compared to other remedies they have used. Of them, 249 fully answered the survey and were included in the research analysis.

The scale was 1 to 5, with 5 meaning the respondents were very happy with FISST and 1 meaning that they preferred to use home remedies.

The respondents were primarily adults over 18 (70%) and were half female and half male. Nearly 80% of the respondents were white.

As far as frequency of hiccups, 69% reported having them at least once a month, and most cases (65%) were transient, less than two hours in duration.

Clinical trial is goal

Future directions include conducting a double-blind clinical trial in Europe and America that gives FISST to one group of trial enrollees and a non-functional, sham device to another group. The challenge is developing something that resembles FISST but doesn't work, Dr. Seifi said.

Credit: 
University of Texas Health Science Center at San Antonio